Co-Authors
This is a "connection" page, showing publications co-authored by ANISHA PATEL and OMAR PACHA.
Connection Strength
3.852
-
Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol. 2021; 1342:319-330.
Score: 0.760
-
Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol. 2020; 1244:235-246.
Score: 0.709
-
Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol. 2018; 995:117-129.
Score: 0.617
-
Skin Reactions to Immune Checkpoint Inhibitors. Adv Exp Med Biol. 2017; 995:175-184.
Score: 0.576
-
A retrospective case series of eight patients with epidermal growth factor receptor inhibitor-induced cutaneous toxicities managed with dupilumab. JAAD Case Rep. 2024 Dec; 54:17-22.
Score: 0.246
-
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 2022 03 01; 128(5):975-983.
Score: 0.201
-
Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer. 2022 Feb; 30(2):989-994.
Score: 0.199
-
Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies. Dermatol Surg. 2021 06 01; 47(6):775-779.
Score: 0.195
-
Characterization of Cutaneous Adverse Events Associated With PI3K Inhibitors in 11 Patients. J Immunother Precis Oncol. 2020 Nov; 3(4):141-146.
Score: 0.188
-
Erratum to "Periorbital edema associated with alpelisib" [Cancer Treatment and Research Communications 32 (2022) 100596]. Cancer Treat Res Commun. 2022; 33:100654.
Score: 0.054
-
A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol. 2022 12; 87(6):1394-1395.
Score: 0.053
-
Periorbital edema associated with alpelisib. Cancer Treat Res Commun. 2022; 32:100596.
Score: 0.053